20 results about "Hematopoietic progenitor cells" patented technology

Methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells are disclosed. The methods can involve stage-specific differentiation from stem cells or stem cell-derived hematopoietic progenitor cells through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells.

Disclosed are methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells. The methods may relate to stage-specific differentiation from stem cells or stem-cell derived hematopoietic progenitors through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells.

The invention provides application of SP140 in regulating and controlling differentiation of pluripotent stem cells to hematopoietic stem cells and / or hematopoietic progenitor cells, and relates to the technical field of cell drug preparation. The expression of SP140 in human pluripotent stem cells (hPSC) or in the differentiation process of the human pluripotent stem cells is reduced on the gene level and the protein level, and the human pluripotent stem cells are promoted to be differentiated into human hematopoietic stem cells (HSC) with multiple transplantation potential. The method not only realizes in-vitro regeneration of the hematopoietic stem cells and / or hematopoietic progenitor cells, but also has the characteristics of short differentiation period, high differentiation efficiency and reduction of culture time and cost, and the prepared hematopoietic stem cells express typical biomarkers and have good multi-transplantation chimeric ability. The invention provides a new way for the source of hematopoietic stem cells required by regenerative medicine and treatment of blood and related diseases.

The invention relates to the field of biomedicine, and discloses application of EPTMPA in hematopoietic stem cell in-vitro amplification culture. The invention identifies a brand-new novel small molecule compound EPTMPA capable of remarkably promoting in-vitro expansion and in-vivo transplantation of hematopoietic stem cells and hematopoietic progenitor cells of umbilical cord blood, and the novel small molecule compound EPTMPA can remarkably promote in-vitro expansion of CD34 + hematopoietic stem cells and hematopoietic progenitor cells and maintain the stem property and differentiation potential. EPTMPA is a new discovery and new way for in-vitro amplification of hematopoietic stem cells, but needs more studies to understand the action mechanism, targeting genes and proteins of the hematopoietic stem cells and the regulation effect on self-renewal and differentiation balance of the stem cells. The researches are of great significance to clinical application and product development in the future.

A hematopoietic stem cell (HSC) proliferation medium includes a basal medium, 0.1 ng / mL to 200.0 ng / mL of thrombopoietin (TPO), 0.1 ng / mL to 200.0 ng / mL of stem cell factor (SCF), 0.1 ng / mL to 20.0 ng / mL of interleukin-3 (IL-3), 0.1 ng / mL to 100.0 ng / mL of interleukin-6 (IL-6), 0.1 ng / mL to 200.0 ng / mL of Flt-3 ligand (FL), 0.1 μg / mL to 20.0 μg / mL of insulin, 0.1 μg / mL to 120.0 μg / mL of transferrin, 0.1 g / L to 3.0 g / L of human serum albumin (HSA), 0.1 μM to 4.0 μM of pyrimido-indole derivative UM729, and 0.1 μM to 2.0 μM of aryl hydrocarbon receptor (AhR) antagonist StemRegenin 1 (SR1). Methods for in vitro proliferation of hematopoietic stem cells (HSCs) and in vitro production of hematopoietic progenitor cells (HPCs) using the HSC proliferation medium are also provided.

The invention provides application of a targeted histone H4K77 acetylation modified substance in preparation of a medicine for delaying immune aging, a modified stem progenitor cell and application of the modified stem progenitor cell, and belongs to the technical field of medicine. The target histone H4K77 acetylation modification or acetylation-like modification substance is a substance for increasing the histone H4K77 acetylation modification level or acetylation-like modification level in hematopoietic stem cells and / or hematopoietic progenitor cells. It is found for the first time that by increasing histone H4K77 acetylation modification or acetylation-like modification, immune senescence and systemic senescence caused by immune senescence can be effectively delayed, and immune senescence and systemic senescence related diseases caused by immune senescence can be treated. The invention provides a new choice for clinically delaying immune senescence and systemic senescence caused by immune senescence and treating immune senescence and systemic senescence related diseases caused by immune senescence, and has a wide application prospect.

Provided are DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, that bind to or target a target site in a DLL4 gene or a VCAM1 gene. In some embodiments, the provided DNA-targeting systems promote transcriptional activation of such genes to promote differentiation of hematopoietic progenitor cells into a differentiated population of cells, such as lymphoid progenitor or lymphoid cells. Also provided herein are methods and uses related to the provided compositions, for example in facilitating lymphoid progenitor cell differentiation.

This invention discloses a traditional Chinese medicine composition for treating neutropenia and / or T-cell cytopenia, its preparation method, and its application. The composition mainly consists of Astragalus membranaceus, Angelica sinensis, ginseng / Codonopsis pilosula, Ganoderma lucidum, Lycium barbarum, and Glycyrrhiza uralensis in a specific ratio. It has a dual effect of increasing neutrophil count and promoting thymic development and T-cell function (enhancing T-cell function). Through multiple pathways, including stimulating hematopoietic progenitor cell proliferation and differentiation, improving the thymic microenvironment, and activating innate and adaptive immunity, it effectively improves the state of reduced immune cells and enhances the body's anti-infection ability.

The invention discloses an amplification culture medium, an amplification method and application of an iPSC (induced pluripotent stem cell) derived hematopoietic progenitor cell population, and relates to the technical field of cell culture. According to the amplification culture medium provided by the invention, animal-derived components are replaced by chemical small molecule combinations, so that the safety of cell products is remarkably improved; the yield of NK cells cultured by the culture medium is greatly increased, the HPC amplification multiple is increased to 2.5 times or more of that of a traditional process by adding tranexamic acid, and the bottleneck of industrial production is broken through. The method provided by the invention improves the process stability. The cells amplified according to the method provided by the invention strengthen the pertinence of lung cancer treatment.

Disclosed are Hematopoietic Progenitor Kinase 1 (HPK1) degradation / disruption compounds including a HPK1 ligand, a degradation / disruption tag and a linker, and methods for use of such compounds in the treatment of HPK1-mediated diseases.

Provided herein are methods for expanding populations of hematopoietic stem cells (HSCs) or hematopoietic progenitor cells (HPCs) using extracellular vesicles isolated from hematopoietic stem cells (HSC-derived EVs) or from HPCs (HPC-derived EVs). Also provided are methods of using the isolated HSC-derived EVs and / or HPC-derived EVs as well as the HSCs and HPCs generated by or exposed to the methods disclosed herein.

This invention provides a method for producing NK cells from undifferentiated stem cells without using feeder cells in serum-free culture medium. [Solution] A method for producing NK cells without using feeder cells, comprising culturing undifferentiated stem cells in a serum-free medium containing BMP4 and a GSK-3 inhibitor to form embryoid bodies, culturing them in a serum-free medium containing VEGF, SCF, and a TGF-β inhibitor, culturing them in a serum-free medium without a TGF-β inhibitor containing VEGF and SCF to differentiate them into hematopoietic progenitor cells, culturing them in a serum-free medium containing IL-7, SCF, Flt-3L, IL-15, and IL-3, culturing them in a serum-free medium without an IL-3 containing IL-7, SCF, Flt-3L, and IL-15 to differentiate them into NK progenitor cells, and culturing them in a serum-free medium containing IL-2, IL-7, SCF, Flt-3L, IL-15, and a serum substitute to differentiate them into mature NK cells.

The present application relates to methods for expanding hematopoietic stem cells (HSC) and / or hematopoietic progenitor cells (HPC) ex vivo and / or in vivo. The methods comprise culturing the HSCs and / or HPCs in the presence of a selective 5-Hydroxytryptamine Receptor 1F (HTR1F) agonist and / or of a Thyroid Hormone Receptor Beta (THRB) agonist, and / or in an air-liquid interface (ALI) culture system. The expanded HSCs and / or HPCs, which maintain engraftment and immune reconstitution properties, may be administered to subjects suffering from various diseases including cancer, immunodeficiencies, myelodysplastic syndrome (MDS) or anemia. The present application also relates to the use of HTR1F and / or THRB agonists for stimulating HSC and / or HPC expansion, and for increasing the number of immune cells or for reconstituting the immune system, in vivo.

A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.

Compositions and methods for delivering a protein of interest such as a cell homing molecule (e.g., CXCR4) into host cells (e.g., to hematopoietic cells). The compositions and methods provided herein may be used to enhance homing and long-term engraftment of hematopoietic cells post transplantation.

The method for producing human macrophages comprises a culture step of culturing human hematopoietic progenitor cells in a culture medium that does not substantially contain either a macrophage colony stimulating factor or a granulocyte-macrophage colony stimulating factor in the presence of a TREM2 signal activator.

Compositions and methods are provided relating to FOXP3 gene edited hematopoietic cells, include hematopoietic stem and progenitor cells, lymphoid progenitor cells, and CD4+ T cells. The gene edited cells are useful in cellular therapy to restore normal immune functions and promote immune tolerance. In particular, CD4edFOXP3 T cells, which may be differentiated from FOXP3 gene edited hematopoietic progenitor cells, can physiologically express functional FOXP3 and exert normal immune responses as effector T cells or have immune suppressive characteristics as naturally occurring Treg cells.

The invention discloses a multi-kinase inhibitor, a PROTACs target protein ligand as well as a synthesis method and application thereof, and the multi-kinase inhibitor is a compound with a structure as shown in a formula (I), and a stereoisomer or pharmaceutically acceptable salt of the compound. The invention relates to a compound which has inhibitory activity on kinases such as mixed lineage kinase 3 (MLK3, FMS-like tyrosine kinase 3 (FLT3), hematopoietic progenitor cell kinase 1 (HPK1) and the like, recruits related kinases and is used for developing protein degradation chimera (PROTACs) target heads, and a preparation method and application of the compound, and the compound can inhibit the activity of MLK3, FLT3 and HPK1 and is used for developing PROTACs, FLT3 and HPK1. The pharmaceutical composition is used for treating various diseases including cancers, immune regulation, autoimmunity and the like. (I).

Described herein are bifunctional compounds of Formula I, compositions comprising the compound of Formula I, and methods of using the same, in treating diseases, disorders, or conditions mediated by the inhibition of certain kinases, such as hematopoietic progenitor kinase 1 (HPK1).